Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed a ...

CONMED Corporation (CNMD) delivered third-quarter 2024 adjusted earnings per share (EPS) of $1.05, which beat the Zacks Consensus Estimate of 99 cents by 6.1%. The bottom line improved 16.7% from the year-ago level.GAAP EPS for the quarter was $1.57 compared with 50 cents in the year-ago period.The company’s shares have lost 40.4% so far this years compared with the industry’s decline of 1.5%. The broader S&P 500 Index has gained 22.9% in the same time frame.Image Source: Zacks Investment ResearchRevenues i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Common Stock, $0.01 par value CNMD NYSE Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the ...

财务数据和关键指标变化 - 第三季度总销售额为3.167亿美元，同比增长4%，按固定汇率计算增长4.3% [7] - GAAP净收入为4900万美元，较2023年第三季度的1580万美元显著增长 [8] - 调整后的净收入为3270万美元，同比增长15%，调整后的每股收益为1.05美元，同比增长16.7% [8][32] 各条业务线数据和关键指标变化 - 全球普通外科收入增长3.6%，美国普通外科收入增长7.4%，国际普通外科收入下降5% [28] - 美国骨科销售增长7.4%，国际骨科销售增长3.9% [26] - AirSeal在美国的资本销售持续强劲增长，需求未见减弱 [21][29] 各个市场数据和关键指标变化 - 美国市场销售增长7.4%，国际市场销售增长0.2% [26] - 第三季度国际销售在2023年表现强劲，增长15.1% [26] 公司战略和发展方向和行业竞争 - 公司计划继续专注于提高服务水平，尤其是在运动医学领域 [27] - 公司在骨科业务上采取积极措施以改善市场份额，尽管受到供应链问题的影响 [23][47] 管理层对经营环境和未来前景的评论 - 管理层对未来的信心依然强烈，预计将恢复加速的销售增长和盈利增长 [9][50] - 管理层提到，尽管受到飓风影响，仍在努力恢复生产能力 [35][36] 其他重要信息 - 公司在第三季度的现金流为5120万美元，较2023年第三季度的4610万美元有所增加 [34] - 长期债务为9.4亿美元，杠杆比率为3.6倍 [34] 问答环节所有提问和回答 问题: 关于普通外科的表现 - 普通外科的表现低于预期，主要是由于去年第三季度的强劲表现和资本设备收入下降近10% [40][41] 问题: 骨科供应链的影响 - 骨科业务的供应链问题仍在持续，预计影响将延续到2024年 [43] 问题: 2025年的增长预期 - 管理层未提供具体的2025年指导，表示将于2025年1月提供更详细的财务展望 [50] 问题: 关于烟雾排放的质量问题 - 烟雾排放的质量问题在第二季度已解决，第三季度的表现有所改善 [54] 问题: 2025年的优先事项 - 新任CEO表示将专注于与客户、员工和股东的沟通，并推动公司的持续增长 [56]

For the quarter ended September 2024, Conmed (CNMD) reported revenue of $316.7 million, up 4% over the same period last year. EPS came in at $1.05, compared to $0.90 in the year-ago quarter. The reported revenue represents a surprise of -0.55% over the Zacks Consensus Estimate of $318.46 million. With the consensus EPS estimate being $0.99, the EPS surprise was +6.06%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

Conmed (CNMD) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.90 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 6.06%. A quarter ago, it was expected that this medical technology company would post earnings of $0.92 per share when it actually produced earnings of $0.98, delivering a surprise of 6.52%. Over the last four quarters, the ...

业绩总结 - Q3 2024全球收入为3.167亿美元，其中普通外科收入为1.862亿美元，骨科收入为1.305亿美元[11] - Q3 2024全球收入增长率为4.3%，其中国内增长7.4%，国际增长0.2%[11] - 2024财年预计收入在13.05亿到13.15亿美元之间，增长率约为5%到6%[15] - 骨科手术的收入为4.05亿美元，普通外科的收入为5.56亿美元，合计收入为9.61亿美元[13] - 单次使用产品的收入为8.148亿美元，占总收入的85%[14] - Q3 2024单次使用产品的全球收入增长率为6.9%[12] 未来展望 - 预计2024年调整后的每股收益（EPS）在1.18到1.23美元之间，增长率约为11%到16%[11] - 2024年骨科手术的EPS预计增长在14.5%到16.5%之间[15] - 2024年普通外科的EPS预计增长在16%到17%之间[15] 市场策略 - 公司在大市场中寻求高增长、高利润的产品组合，以提高市场份额[8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.01 par value CNMD NYSE FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 4, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organizati ...

Conmed (CNMD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 30. ...